Fig. 1.

Pain-free and most bothersome symptom-free (MBS-free) at 2 h following lasmiditan treatment were similar in patients using and not using migraine preventive medications. Patients using and not using migraine preventive medications treated a migraine headache with lasmiditan (LTN) 50 mg, 100 mg, or 200 mg or placebo (PBO). At 2 h postdose, patients rated their pain and presence or absence of nausea, phonophobia, or photophobia. Colored bars show the percentages of patients reporting a complete absence of pain (1a) or MBS (1b) at 2 h. Comparisons of lasmiditan effect in the group of patients using versus not using preventive medications were not significant for any treatment group for either pain-free or MBS-free (all interaction p-values > 0.1)